ArticleJournal of neuroinflammation2026
Activation of the NR3C1-STAT3-SLC6A2 signaling axis by a cyanidin-3-O-glucoside-enriched anthocyanin preparation attenuates neuroinflammation and pain hypersensitivity in intervertebral disc degeneration.
Article in Journal of neuroinflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors.
Funding
Abstract
backgroundIVDD is a major global health burden and a leading cause of chronic low back pain, yet disease-modifying therapies remain limited. Anthocyanins are natural anti-inflammatory compounds with potential neuroprotective activity, but their roles in IVDD-related neuroinflammation and nociceptive sensitization are unclear.
methodsAnthocyanins used in this study were a commercially standardized preparation (≥ 98% purity), in which cyanidin-3-O-glucoside (C3G) constituted the predominant component as confirmed by LC–MS analysis. IVDD was established by needle puncture in rats and conditional Cre–loxP mice. Mechanical and thermal pain behaviors were assessed, and disc pathology was evaluated by imaging and histological/biochemical analyses. IL-1β–stimulated NP cultures and NP–DRG co-cultures were used to model neuron–disc interactions. Mechanistic studies combined pharmacological modulation and genetic targeting of NR3C1/STAT3 with assays of NR3C1 nuclear translocation, NR3C1–STAT3 interaction, and STAT3 binding to the SLC6A2 promoter.
resultsCyanidin-3-O-glucoside (C3G)–enriched anthocyanin preparation reduced IVDD-associated neuroinflammation and pain hypersensitivity, improved disc degeneration, and decreased NP apoptosis and inflammatory mediator release. Mechanistically, anthocyanins activated the NR3C1–STAT3–SLC6A2 axis, enhancing NR3C1 nuclear localization, promoting NR3C1–STAT3 coupling, and restoring SLC6A2 expression in sensory neurons. Disrupting NR3C1 or STAT3 weakened these protective and antinociceptive effects.
conclusionsC3G-enriched anthocyanins alleviate IVDD-related neuroinflammation and pain primarily via the NR3C1–STAT3–SLC6A2 signaling axis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.